---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041269"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:25:10.720943+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Roivant Q2 net loss $113.5M; brepocitinib Phase 3 DM trial succeeds on all endpoints

## Summary
- Brepocitinib 30 mg met primary and all nine key secondary endpoints in Phase 3 VALOR DM study; NDA filing planned H1 2026.
- Net loss attributable to Roivant $113.5M ($0.17/sh) vs $230.2M ($0.31) a year ago; revenue $1.6M.
- Cash and marketable securities $4.4B as of Sept 30, 2025; R&D spend $164.6M (up 15% YoY).
- Immunovant batoclimab TED: first Phase 3 readout by end-2025, but both studies to release concurrently in H1 2026 due to competitive dynamics.
- Favorable Markman ruling in Pfizer/BioNTech LNP litigation; Moderna jury trial scheduled March 2026.

## SEC filing metadata
- accession: 0001140361-25-041269
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036125041269/0001140361-25-041269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036125041269/ef20058314_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041269
- JSON: https://secwatch.observer/filing/0001140361-25-041269.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041269.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.